Advertisement
 
YOU ARE HERE: LAT HomeCollectionsVaccines

Study bolsters hopes for prostate cancer vaccine rejected by FDA

The vaccine, Provenge, extended life an average of four months, nearly twice as long as the best available chemotherapy, researchers say.

April 29, 2009|Thomas H. Maugh II

A controversial prostate cancer vaccine that previously had been rejected by the Food and Drug Administration improves survival of patients with the advanced form of the disease more than existing treatments and should be brought to market, researchers said Tuesday.

The therapeutic vaccine, called Provenge, extended average survival by four months compared with a placebo, nearly twice as long as the best available chemotherapy, and increased three-year survival by 38%, researchers said at a Chicago meeting of the American Urological Assn.

"This is going to change the way we treat . . . metastatic prostate cancer," said Dr. David Penson, a urologist at USC's Norris Comprehensive Cancer Center. "Any patient who has this form of cancer, this is the drug they are going to want, and it is going to be first-line therapy."

"This will be much easier for patients than going through chemotherapy because there are no side effects," added Dr. Stanton Gerson, director of the University Hospitals Ireland Cancer Center in Cleveland. Prostate cancer patients "have never had cell therapy or a vaccine as an option before. Now they will."

Dr. Jonathan W. Simons, president of the Prostate Cancer Foundation, said in an e-mailed statement, "The results validate 16 years of modern research to harness a patient's own immune system to fight their prostate cancer."

Both Penson and Gerson participated in the study, but neither has financial links to Dendreon Corp. of Seattle, which developed Provenge. The foundation provided support for some of the initial research on the vaccine.

As a therapeutic vaccine, Provenge is designed to treat the disease rather than prevent it. Physicians collect specialized immune cells called dendritic cells from the patient's blood, mix them with proteins collected from the surface of tumor cells and inject them back into the patient in three doses at two-week intervals.

In a previous study released in 2007, Dendreon found that the vaccine increased survival in patients with metastatic disease by 18 weeks compared with patients given a placebo. After three years, 34% of those in the vaccine group survived, compared with 11% of those in the placebo group.

An FDA advisory committee recommended that the vaccine be approved for marketing, but the FDA disagreed, arguing that the study did not provide evidence the vaccine slowed progression of tumors.

The decisions provoked outrage among cancer patients. "Since 2007, I have watched men who could have been helped by Provenge suffer and die from prostate cancer," Thomas A. Farrington, founder and president of the Prostate Health Education Network, said in a statement. "I urge FDA to move as quickly as possible now to make Provenge available to patients."

The new double-blind study involved 512 patients with advanced prostate cancer. Two-thirds received Provenge, and the rest received a placebo. Dr. Paul Schellhammer of Eastern Virginia Medical School in Norfolk, Va., said that median survival in the Provenge group was 26 months, compared with 22 months in the placebo group.

That may seem like a short time, experts said, but drugs that provide shorter survival are routinely approved.

"The ability to boost survival for patients is the gold standard end point in prostate cancer clinical trials," said Dr. Ira D. Sharlip, a urologist at UC San Francisco, a spokesman for the urology association.

The current treatment for such patients is Taxotere, known generically as docetaxel, which extends survival two to three months at most and has often-disabling side effects. Many men refuse to take it, Penson said. He has seen many patients taking it end up in a wheelchair from its side effects, which can include bone and muscle pain, allergic reactions, decreases in white and red blood cells, and neuropathy.

But with Provenge, "they might have a little fever, and the next day they are out playing golf," Sharlip said.

Dendreon officials said they would reapply to the FDA sometime this year. They have not said how much the therapy might cost. An estimated 186,000 American men develop prostate cancer each year, and about 28,660 die of it.

--

thomas.maugh@latimes.com

Advertisement
Los Angeles Times Articles
|
|
|